Patient characteristics
SD, acute lung injury, ARDS
ARDS, ACUTE RESPIRATORY DISTRESS SYNDROME
The plasma concentration of MMP-3 was determined at day 0 and day 3 in 100 samples from ALTA (50 in the albuterol treatment group and 50 in the placebo group). Baseline characteristics did not differ between albuterol and treatment groups of the ALTA trial (Table Demographics by MMP-3 level and change in MMP-3 from day 0 to 3All data are presented as n (%), mean ± SD, and median (interquartile range) unless otherwise notedALI: acute lung injury; ARDS: acute respiratory distress syndrome; APACHE III: Acute Physiology and Chronic Health Evaluation III; ICU: intensive care unit; MMP-3: matrix metalloproteinase-3; Vfd: ventilator free days